• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

    21.25 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,528
    Open 21.25
    Bid (Size) 21.30 (400)
    Ask (Size) 21.75 (100)
    Prev. Close 21.25
    Today's Range 21.25 - 21.25
    52wk Range 19.69 - 28.35
    Shares Outstanding 162,625,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗
    ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide... 
    Via MarketBeat
    News headline image
    ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗
    ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders,... 
    Via MarketBeat

    Performance

    YTD
    -19.2%
    -19.2%
    1 Month
    -2.5%
    -2.5%
    3 Month
    -3.3%
    -3.3%
    6 Month
    -20.7%
    -20.7%
    1 Year
    -4.3%
    -4.3%

    More News

    Read More
    News headline image
    Acadia (ACAD) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗
    Via Chartmill
    Topics Earnings
    ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗
    Via Chartmill
    News headline image
    Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
    Via Stocktwits
    News headline image
    ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
    ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
    What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
    The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 21.25
    When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 06/10/26 04:00 PM ET
    What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
    The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.46B
    How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
    ACADIA Pharmaceuticals Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.